Pneumonia risk in COPD patients initiating extrafine Fixed Dose Combination (FDC) with beclometasone dipropionate (ef-FDC-BDP) versus long-acting bronchodilators (LABD)

David Price, William Henley, Victoria Carter, Derek Skinner, Rebecca Vella, Alberto Papi, Leonardo M Fabbri, Huib AM Kerstjens, Nicolas Roche, Dave Singh, Claus F Vogelmeier, Elif Şen, José Eduardo Delfini Cançado, Elena Nudo, Sara Barile, George Georges

Research output: Contribution to conferenceAbstractpeer-review

Abstract

Background: The use of extrafine inhaled corticosteroid (ICS) formulations in COPD
treatment reduce exacerbations and allow lower doses possibly reducing pneumonia risk.
Original languageEnglish
Publication statusAccepted/In press - 29 Jul 2021
EventERS International Congress 2021 - Virtual event
Duration: 5 Sept 20218 Sept 2021
https://www.ersnet.org/congress-and-events/congress/

Conference

ConferenceERS International Congress 2021
Abbreviated titleERS
Period5/09/218/09/21
Internet address

Fingerprint

Dive into the research topics of 'Pneumonia risk in COPD patients initiating extrafine Fixed Dose Combination (FDC) with beclometasone dipropionate (ef-FDC-BDP) versus long-acting bronchodilators (LABD)'. Together they form a unique fingerprint.

Cite this